Find a Dentist
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants
BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023
BIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023
Receive updates straight into your inbox
